Read Verzenio Indications and Important Treatment Considerations

Verzenio, also known by its generic name abemaciclib, is a targeted cancer medicine used for certain adults with hormone receptor positive and HER2 negative breast cancer. Its approved uses include specific forms of high risk early breast cancer and advanced or metastatic breast cancer.

Verzenio is a cyclin dependent kinase 4 and 6 inhibitor. According to the current US prescribing information, it is used for particular adults with HR positive, HER2 negative breast cancer. The specific indication depends on whether the cancer is early, advanced, or metastatic and whether previous treatment has been given.

For early breast cancer, Verzenio is indicated with endocrine therapy for adults with HR positive, HER2 negative, node positive disease that has a high risk of recurrence. For advanced or metastatic disease, its approved uses include treatment with an aromatase inhibitor as initial endocrine based therapy, treatment with fulvestrant after progression following endocrine therapy, and monotherapy in certain patients whose disease has progressed after endocrine therapy and prior chemotherapy in the metastatic setting.

Key points include:

  • Verzenio is used for specific HR positive and HER2 negative breast cancers.
  • Early breast cancer use is limited to eligible patients with node positive disease at high risk of recurrence.
  • Advanced or metastatic treatment may involve an aromatase inhibitor, fulvestrant, or Verzenio alone, depending on the treatment setting.
  • The appropriate treatment combination depends on the individual's clinical history and previous therapies.

Important Treatment Considerations and Safety

Treatment with Verzenio requires attention to dosing, tolerability, other medicines, and potential adverse reactions. The prescribing information states that dose interruptions or reductions may be needed when adverse reactions occur. Patients should take the medicine exactly as prescribed and should not change the dose without guidance from their healthcare professional.

Important considerations include:

  • Diarrhea: This can occur during treatment and may sometimes become severe. Prompt management is important to reduce the risk of dehydration and complications.
  • Blood cell counts: Neutropenia can occur, so healthcare professionals may monitor blood counts during treatment.
  • Liver function: Hepatotoxicity is an important warning, making appropriate liver function monitoring relevant.
  • Lung problems: Interstitial lung disease or pneumonitis is an identified safety risk.
  • Blood clots: Venous thromboembolism is another important potential risk.
  • Pregnancy: Verzenio can cause fetal harm, so pregnancy related precautions should be discussed with a healthcare professional.
  • Drug interactions: Other medicines can affect Verzenio exposure, making a complete medication review important.
  • Individualized dosing: Treatment may need adjustment based on adverse reactions, liver function, and other clinical factors.

Verzenio has specific approved indications for certain patients with HR positive, HER2 negative breast cancer, covering selected high risk early disease and advanced or metastatic disease. Because treatment choices and safety considerations vary by individual, patients should discuss their diagnosis, previous therapies, other medicines, and potential risks with their healthcare team. This article provides general educational information only and is not a substitute for professional